MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Operator Good morning, and welcome to MiNK Therapeutics' Third Quarter 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdic ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Kalpit Patel - B. Riley Securities Jack Allen - Baird Matthew Phipps - William Blair Operator Good day, and welcome to the MiNK Therapeutics Second Quarter 2022 Earnings Conference Call. Please note, today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 82-2142067 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 149 Fifth Avenue | | | Suite 500 | | | New York, NY | 10010 | | (Address of principal executive offices) | (Zip Code) | | Registrant's telephone number, including area code: 212- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jur ...